Compare · AAPG vs NVS
AAPG vs NVS
Side-by-side comparison of Ascentage Pharma Group International (AAPG) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AAPG and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVS is the larger of the two at $303.64B, about 247.6x AAPG ($1.23B).
- Over the past year, AAPG is down 57.5% and NVS is up 24.3% - NVS leads by 81.8 points.
- AAPG has been more active in the news (7 items in the past 4 weeks vs 5 for NVS).
- NVS has more recent analyst coverage (25 ratings vs 11 for AAPG).
- Company
- Ascentage Pharma Group International
- Novartis AG
- Price
- -
- -
- Market cap
- $1.23B
- $303.64B
- 1M return
- -11.00%
- +5.95%
- 1Y return
- -57.54%
- +24.30%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2025
- News (4w)
- 7
- 5
- Recent ratings
- 11
- 25
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Latest AAPG
- Amendment: SEC Form 6-K/A filed by Ascentage Pharma Group International
- SEC Form 6-K filed by Ascentage Pharma Group International
- Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib
- SEC Form 6-K filed by Ascentage Pharma Group International
- Ascentage Pharma to Present Data from Multiple Trials, Including an Oral Presentation of APG-5918 at ASH 2026
- Ascentage Pharma to Participate in Two Upcoming Investor Conferences in London
- SEC Form 6-K filed by Ascentage Pharma Group International
- SEC Form 6-K filed by Ascentage Pharma Group International
- SEC Form 6-K filed by Ascentage Pharma Group International
- Ascentage Pharma’s Lisaftoclax Granted Breakthrough Therapy Designation in China for Treatment-Naïve CLL/SLL
Latest NVS
- SEC Form 6-K filed by Novartis AG
- SEC Form FWP filed by Novartis AG
- FDA Approval for LAMPRENE issued to NOVARTIS
- Novartis AG downgraded by Deutsche Bank
- SEC Form 6-K filed by Novartis AG
- Big Pharma Setbacks Create a New Wave of Rebound Plays
- Novartis AG upgraded by HSBC Securities
- Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
- RBC Capital Mkts initiated coverage on Novartis AG
- Novartis AG downgraded by Deutsche Bank